Alabama
Birmingham; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Birmingham; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Birmingham; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Birmingham; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Mobile; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Montgomery; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Pell City; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Arizona
Tucson; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Tucson; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Arkansas
Fayetteville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
California
La Jolla; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
La Jolla; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Oceanside; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Oceanside; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Orange; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Palo Alto; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Palo Alto; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Roseville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
San Francisco; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Colorado
Colorado Springs; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Golden; Rocky Mountain Clinical Research
Clinical Trial of CCX282-B in Individuals With Moderately to Severely Active Crohn’s Disease.
Golden; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Golden; Rocky Mountain Clinical Research, Inc.
A Pilot Study of the Safety and Efficacy of ALX-0600 in Subjects with Moderately Active Crohn’s Disease.
Golden; Rocky Mountain Clinical Research, Inc.
Active Crohn's Disease: International, Multicenter, Double-Blind, Placebo-controlled study for moderate to severe Crohn's Disease.
Golden; Rocky Mountain Clinical Research, Inc.
An investigational research trial to assess the safety and efficacy of a study drug in patients with active Crohn's disease.
Lakewood; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Lakewood; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Lakewood; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Littleton; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Wheat Ridge; Western States Clinical Research, Inc.
New Research Takes Aim At Crohn's Disease
Wheat Ridge; Western States Clinical Research, Inc.
Crohn's Disease Clinical Research Study
Connecticut
Waterbury; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Waterbury; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Florida
Clearwater; Clinical Research of West Florida, Inc.
Crohn's disease research study
Clearwater; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Clearwater; Clinical Research of West Florida, Inc.
Do you suffer from Crohn's Disease?
Clearwater; Clinical Research of West Florida, Inc.
Crohn's disease research study
Clearwater; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Gainesville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Gainesville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Hialeah; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Hialeah; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Hollywood; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Jacksonville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Jacksonville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Jacksonville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Jacksonville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
New Port Richey; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
North Miami Beach; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
North Miami Beach; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
North Miami Beach; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Palm Harbor; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Sarasota; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Sarasota; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
St. Petersburg; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
St. Petersburg; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
St. Petersburg; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Winter Park; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Winter Park; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Georgia
Marietta; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Marietta; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Savannah; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Savannah; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Illinois
Arlington Heights; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Chicago; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Chicago; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Lombard; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Indiana
Bloomington; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Bloomington; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Iowa
Davenport; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Kansas
Topeka; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Topeka; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Kentucky
Bowling Green; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Bowling Green; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Lexington; University of Kentucky Chandler Medical Center
Do you have Crohn’s disease or ulcerative colitis?
Lexington; University of Kentucky Chandler Medical Center
Do you have Crohn’s disease or ulcerative colitis?
Lexington; University of Kentucky Chandler Medical Center
Relatives of Inflammatory Bowel Disease Patients Needed for Health Questionnaire
Louisville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Louisville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Louisiana
Metairie; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Metairie; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Metairie; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Metairie; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Monroe; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Maryland
Annapolis; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Annapolis; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Annapolis; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Chevy Chase; Chevy Chase Clinical Research/Metropolitan Gastroenterology Group
Crohn's Disease - Working for a Better Tomorrow
Chevy Chase; Metropolitan Gastroenterology Group/Chevy Chase Clinical Research
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
Laurel; Maryland Digestive Disease Research, LLC
Crohn's Disease
Prince Frederick; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Townson; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Massachusetts
Newton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Worcester; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Michigan
Chesterfield; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Chesterfield; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Chesterfield; UCB Clinical Trial Call Center![[*]](../images/newtiny.gif)
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Dearborn; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Troy; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Troy; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Minnesota
Minneapolis; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Rochester; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Rochester; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Rochester; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Mississippi
Ocean Springs; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Ocean Springs; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Missouri
Kansas City; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Kansas City; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Mexico; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Mexico; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
New Jersey
Cedar Knolls; Gastroenterology Research Associates, LLC
A Clinical Research Study for Adults with Moderately-to Severely-Active Crohn’s Disease
Egg Harbor Township; Atlantic Gastroenterology Associates
Do You Have Crohn's Disease? Have You Received Infliximab (Remicade) Therapy?
Egg Harbor Township; Atlantic Gastroenterology Associates
Do you suffer from Crohn's disease and have been unable to find a successful treatment option?
Egg Harbor Township; Atlantic Gastroenterology Associates
Do you have Crohn's Disease?
New York
Manhasset; Biomedical Research Alliance of New York
Crohn’s Disease - Adults
Mineola; Winthrop University Hospital Clinical Trials Center
This is a clinical research study for people with active moderate Crohn’s Disease.
Mineola; Winthrop University Hospital Clinical Trials Center
Volunteers needed for a pediatric Crohn’s Disease research study.
New Hyde Park; Biomedical Research Alliance of New York
Crohn’s Disease- Ages 6-17 years old
New York; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
New York; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
New York; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
New York; Mount Sinai Medical Center
A Phase IIIb multicentre, open label induction and double blind comparison of two maintenance schedules evaluating clinical benefit and tolerability of certolizumab pegol, a pegylated Fab fragment of humanized antibody to tumor necrosis factor(TNF) over 26 weeks in patients suffering from Crohn's disease with prior loss of response or intolerance to infliximab.[RPCE05F1501]
New York; Mount Sinai Medical Center
Multi-site Trial of Azathioprine Dosing in Crohn's Disease
New York; Mount Sinai Medical Center
Double-blind, Randomized, Multicenter, Placebo controlled Phase II Study of Efficacy and Safety of HMPL 004 in Subjects with Active Moderate Crohn's Disease [200500401]
New York; Mount Sinai Medical Center
Multi-site Trial of Azathioprine Dosing in Crohn?Æs Disease
New York; Mount Sinai Medical Center
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease.
Protocol M02-403
Syracuse; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Syracuse; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
North Carolina
Chapel Hill; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Chapel Hill; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Charlotte; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Charlotte; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Charlotte; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Charlotte; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Jacksonville; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Raleigh; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Raleigh; Wake Research Associates
Don’t let Crohn’s Disease keep you from your favorite activities
Raleigh; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Raleigh; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Raleigh; Wake Research Associates
Research Study for Crohn's Disease
Raleigh; Wake Research Associates
Do you have suffer from Crohn's Disease?
Raleigh; Wake Research Associates
Do you have Crohn's Disease?
Wilmington; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
North Dakota
Fargo; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Ohio
Beachwood; Gastroenterology Associates of Cleveland, Inc.
Humira for Crohn's Disease
Beachwood; Gastroenterology Associates of Cleveland, Inc.
Research trial now enrolling for Humira ® for Crohn's Disease
Cincinnati; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Cincinnati; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Cincinnati; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Cincinnati; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Cleveland; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Cleveland; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Cleveland; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Cleveland; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Dayton; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Dayton; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Dayton; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Oklahoma
Oklahoma City; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tulsa; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tulsa; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Tulsa; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Pennsylvania
Beaver Falls; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Beaver Falls; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Lancaster; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
South Carolina
Columbia; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Columbia; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Tennessee
Germantown; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Germantown; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Germantown; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Germantown; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Nashville; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Nashville; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Texas
Austin; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Austin; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Houston; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
San Antonio; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Tyler; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Utah
Salt Lake City; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Salt Lake City; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Vermont
Burlington; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Burlington; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Virginia
Charlottesville; University of Virginia
Men and women 18-65 with active Crohn's disease wanted for study
Chesapeake; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Chesapeake; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Norfolk; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Richmond; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Richmond; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Washington
Seattle; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Seattle; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Spokane; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Spokane; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Tacoma; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Tacoma; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Wisconsin
Madison; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Madison; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Milwaukee; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Milwaukee; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Monroe; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Monroe; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
International
Adelaide, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Box Hill, Australia; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Concord, NSW, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Footscray, VIC, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Fremantle, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Parkville, VIC, Australia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Box Hill, Australlia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Bonheiden, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Brussels, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Gent, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Leuven, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Liege, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Roeselare, Belgium; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Abbotsford, British Columbia, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Abbottsford, British Columbia, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Calgary, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Calgary, Alberta, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Edmonton, Alberta, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Hamilton, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kelowna, BC, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kingston, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
London, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Saskatoon, Saskatchewan, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Saskatoon, Saskatchewan, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Toronto, ON, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Toronto, Ontario, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Vancouver, British Columbia, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Winnipeg, Canada; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Winnipeg, Manitoba, Canada; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Winnipeg, Manitoba, Canada; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Vina del Mar, Chile; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Hradec Kralove, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Hradek Kralove, Czech Republic; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Hradek Kralove, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Liberec, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Olomouc, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tabor, Czech Republic; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Zlin, Czech Republic; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tallin, Estonia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tallin, Estonia; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Tartu, Estonia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Haemeenlinna, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Jyvaskylä, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Mikkeli, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tampere, Finland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Frankfurt, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Heidelberg, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Heidleberg, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Jena, Germany; UCB Clinical Trial Call Center
Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
Jena, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Ulm, Germany; UCB Clinical Trial Call Center
Corticosteroid Sparing Effect of Certolizumab
Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Athens, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Heraclion, Crete, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Ioannina, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Piraeus, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Thessaloniki, Greece; UCB Clinical Trial Call Center
Certolizumab Pegol for Treatment of Adult Greek Population With Moderate to Severe Crohn's Disease, Who Failed on Infliximab
Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Budapest, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Gyor, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Nagykanizsa, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Szeged, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Szombathely, Hungary; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Beer Sheva, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Beer Sheva, Israel; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Haifa, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kfar Saba, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Petha Tikva, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Rehovot, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Tel Aviv, Israel; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Roma, Italy; UCB Clinical Trial Call Center
Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
Roma, Italy; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Roma, Italy; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Riga, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Valmiera, Latvia; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Auckland, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Auckland, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Christchurch, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Hamilton, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Newton, Wellington, New Zealand; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Lodz, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Warszawa, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Warszawa, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Wroclaw, Poland; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Bucharest, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Bucharest, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Cluj Napoca, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Constanta, Romania; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Dniepropetrovsk, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Dniepropetrovsk, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Donetsk, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kiev, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kiev, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kyiv, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Kyiv, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Lviv, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
Simferopol, Ukraine; UCB Clinical Trial Call Center
Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
